The evaluation of patient demographics, etiologies and apraclonidine test results in adult Horner's syndrome.
Anhydrosis
Enophthalmos
Horner's syndrome
Miosis
Oculosympathetic paresis
Ptosis
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
19
02
2021
accepted:
21
10
2021
pubmed:
1
11
2021
medline:
13
4
2022
entrez:
31
10
2021
Statut:
ppublish
Résumé
We aimed to demonstrate the patient demographics, etiologies and apraclonidine test results in adult Horner's syndrome. This retrospective study was performed by the analysis of medical data of patients who were given 0.5% apraclonidine test. Patients' past medical history, demographic data, etiologies, accompanying neurological findings and pharmacological test results were assessed. Forty patients (21 females and 19 males) with a mean age of 50.3 ± 11.6 years were evaluated. Apraclonidine 0.5% test was positive in 37 patients (92.5%). An etiology could be identified in 20 patients (central [9 patients, 45%], preganglionic [9 patients, 45%] and postganglionic [2 patients, 10%]). Neurological findings accompanying Horner's syndrome were present in 8 patients. Despite detailed investigations, in a significant number of patients with Horner's syndrome an underlying cause may not be detected. Among the identifiable lesions, central and preganglionic involvements are still the first leading causes of Horner's syndrome. In addition, apraclonidine test may not be positive in all patients and a negative response does not exclude Horner's syndrome.
Identifiants
pubmed: 34718919
doi: 10.1007/s10792-021-02109-0
pii: 10.1007/s10792-021-02109-0
doi:
Substances chimiques
apraclonidine
843CEN85DI
Clonidine
MN3L5RMN02
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1239Subventions
Organisme : Scientific Research Project Coordination Unit of İzmir Democracy University. Project number:TPF-20H04.
ID : TPF-20H04
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Martin TJ (2018) Horner syndrome: a clinical review. ACS Chem Neurosci 9:177–186
doi: 10.1021/acschemneuro.7b00405
Kanagalingam S, Miller NR (2015) Horner syndrome: clinical perspectives. Eye Brain 7:35–46
Bremner F (2019) Apraclonidine is better than cocaine for detection of Horner syndrome. Front Neurol 10:55
doi: 10.3389/fneur.2019.00055
Karti DT, Karti O, Celebisoy N (2019) A rare cause of Horner’s syndrome: cervicothoracic spinal root cysts. Neurol Sci 40:1311–1314
doi: 10.1007/s10072-019-03773-y
Khan Z, Bollu PC. Horner Syndrome. 2021 May 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29763176.
Han J, Park SY, Lee JY (2021) Nationwide population-based incidence and etiologies of pediatric and adult Horner syndrome. J Neurol 268:1276–1283
doi: 10.1007/s00415-020-10270-2
Trobe JD (2010) The evaluation of Horner syndrome. J Neuroophthalmol 30(1):1–2
doi: 10.1097/WNO.0b013e3181ce8145
Gamaleldin OA, Donia MM, Elsebaie NA, Abdelkhalek Abdelrazek A, Rayan T, Khalifa MH (2020) Role of fused three-dimensional time-of-flight magnetic resonance angiography and 3-dimensional t2-weighted imaging sequences in neurovascular compression. World Neurosurg 133:e180–e186
doi: 10.1016/j.wneu.2019.08.190
Razek AAKA, Maher H, Kasem MA, Helmy E (2021) Imaging of congenital cranial dysinnervation disorders: what radiologist wants to know? Clin Imaging 71:106–116
doi: 10.1016/j.clinimag.2020.10.055
Abdel Razek AAK, Gamaleldin OA, Elsebaie NA (2020) Peripheral nerve sheath tumors of head and neck: imaging-based review of world health organization classification. J Comput Assist Tomogr 44:928–940
doi: 10.1097/RCT.0000000000001109
Wilhelm H, Ochsner H, Kopycziok E, Trauzettel-Klosinski S, Schiefer U, Zrenner E (1992) Horner’s syndrome: a retrospective analysis of 90 cases and recommendations for clinical handling. Ger J Ophthalmol 1:96–102
pubmed: 1477633
Sabbagh MA, De Lott LB, Trobe JD (2020) Causes of Horner syndrome: a study of 318 patients. J Neuroophthalmol 40:362–369
doi: 10.1097/WNO.0000000000000844
Maloney WF, Younge BR, Moyer NJ (1980) Evaluation of the causes and accuracy of pharmacologic localization in Horner’s syndrome. Am J Ophthalmol 90:394–402
doi: 10.1016/S0002-9394(14)74924-4
Thompson H, Maxner C, Corbett J. Horner’s syndrome due to damage to the preganglionic neuron of the oculosympathetic pathway. In: Huber A, editor. Symphathetics and the Eye [English Translation]. Stuttgart, Germany: Ferdinand Enke; 1990
Top Karti D, Karti O, Koc AM, Esen O, Celebisoy N (2019) Unilateral Abducens nerve palsy with ipsilateral Horner’s syndrome as an initial manifestation of recurrent nasopharyngeal carcinoma. Neuroophthalmology 44:379–383
doi: 10.1080/01658107.2019.1625931
Morales J, Brown SM, Abdul-Rahim AS, Crosson CE (2000) Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol 118:951–954
pubmed: 10900109
Kong YX, Wright G, Pesudovs K, O’Day J, Wainer Z, Weisinger HS (2007) Horner syndrome. Clin Exp Optom 90:336–344
doi: 10.1111/j.1444-0938.2007.00177.x
Koc F, Kavuncu S, Kansu T, Acaroglu G, Firat E (2005) The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. Br J Ophthalmol 89:1442–1444
doi: 10.1136/bjo.2005.074492
Watts P, Satterfuekd D, Lim MK (2007) Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. J AAPOS 11:282–283
doi: 10.1016/j.jaapos.2007.02.015
Enyedi LB, Freedman SF (2001) Safety and efficacy of brimonidine in children with glaucoma. J JAAPOS 5:281–284
Carlson J, Zabriskie N, Known T, Barbe ME, Scott WE (1999) Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 128:255–256
doi: 10.1016/S0002-9394(99)00083-5
Chen PL, Chen JT, Lu DW, Chen YC, Hsiao CH (2006) Comparing efficacies of 0.5% apraclonidine with 4% cocaine in the diagnosis of horner syndrome in pediatric patients. J Ocul Pharmacol Ther 22:182–187
doi: 10.1089/jop.2006.22.182
Mahoney NR, Liu GT, Menacker SJ, Wilson MC, Hogarty MD, Maris JM (2006) Pediatric Horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 142:651–659
doi: 10.1016/j.ajo.2006.05.047
Kardon R (2005) Are we ready to replace cocaine with apraclonidine in the pharmacologic diagnosis of Horner syndrome? J Neuroophthalmol 25:69–70
pubmed: 15937425
Bohnsack BL, Parker JW (2008) Positive apraclonidine test within two weeks of onset of Horner syndrome caused by carotid artery dissection. J Neuroophthalmol 28:235–236
doi: 10.1097/WNO.0b013e318175d206
Bacal D, Levy SR (2004) The use of apraclonidine in the diagnosis of Horner syndrome in pediatric patients. Arch Ophthalmol 122(276–9):5
Brown SM, Aouchiche R, Freedman KA (2003) The utility of 0.5% apraclonidine in the diagnosis of Horner syndrome. Arch Ophthalmol 121:1201–1203
doi: 10.1001/archopht.121.8.1201
Chen PL, Hsiao CH, Chen JT, Lu DW, Chen WY (2006) Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination. Am J Ophthalmol 142:469–474
doi: 10.1016/j.ajo.2006.04.052
Chu EA, Byrne PJ (2007) Pharmacologic reversal of Horner’s syndrome related ptosis with apraclonidine. Ear Nose Throat J 86:270–273
doi: 10.1177/014556130708600508
Freedman KA, Brown SM (2005) Topical apraclonidine in the diagnosis of suspected Horner syndrome. J Neuroophthalmol 25:83–85
pubmed: 15937427
Garibaldi DC, Hindman HB, Grant MP, Iliff NT, Merbs SL (2006) Effect of 0.5% apraclonidine on ptosis in Horner syndrome. Ophthalmic Plast Reconstr Surg 22:53–55
doi: 10.1097/01.iop.0000196322.05586.6a